153 related articles for article (PubMed ID: 23482591)
1. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel.
Silva AL; Carmo F; Bugalho MJ
Eur J Endocrinol; 2013 Jun; 168(6):795-804. PubMed ID: 23482591
[TBL] [Abstract][Full Text] [Related]
2. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
3. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
5. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
[TBL] [Abstract][Full Text] [Related]
6. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
7. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
8. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
9. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
12. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
13. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
16. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
[TBL] [Abstract][Full Text] [Related]
17. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
18. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
19. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
20. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
